Equillium Net Income
| EQ Stock | USD 1.57 0.03 1.88% |
As of the 16th of February 2026, Equillium shows the Coefficient Of Variation of 770.33, mean deviation of 5.33, and Downside Deviation of 6.49. Equillium technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Equillium Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.4654 | Revenue | Earnings Share (0.58) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.3 M | -7.6 M | |
| Net Loss | -56.2 M | -53.4 M | |
| Net Loss | -7.3 M | -7.6 M | |
| Net Loss | (0.21) | (0.22) | |
| Net Income Per E B T | 0.94 | 0.82 |
Equillium | Net Income | Build AI portfolio with Equillium Stock |
Evaluating Equillium's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Equillium's fundamental strength.
Latest Equillium's Net Income Growth Pattern
Below is the plot of the Net Income of Equillium over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Equillium financial statement analysis. It represents the amount of money remaining after all of Equillium operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Equillium's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Equillium's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.07 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Equillium Net Income Regression Statistics
| Arithmetic Mean | (13,199,036) | |
| Coefficient Of Variation | (127.98) | |
| Mean Deviation | 12,252,210 | |
| Median | (7,260,300) | |
| Standard Deviation | 16,892,272 | |
| Sample Variance | 285.3T | |
| Range | 60.2M | |
| R-Value | (0.44) | |
| Mean Square Error | 246.1T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | (1,463,782) | |
| Total Sum of Squares | 4565.6T |
Equillium Net Income History
Other Fundumenentals of Equillium
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Equillium Net Income component correlations
Equillium Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Equillium is extremely important. It helps to project a fair market value of Equillium Stock properly, considering its historical fundamentals such as Net Income. Since Equillium's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Equillium's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Equillium's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Equillium have expansion opportunities? Factors like these will boost the valuation of Equillium. Projected growth potential of Equillium fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Equillium demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.58) | Revenue Per Share | Quarterly Revenue Growth (0.52) | Return On Assets | Return On Equity |
Equillium's market price often diverges from its book value, the accounting figure shown on Equillium's balance sheet. Smart investors calculate Equillium's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Equillium's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Equillium's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Equillium should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Equillium 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Equillium's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Equillium.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Equillium on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Equillium or generate 0.0% return on investment in Equillium over 90 days. Equillium is related to or competes with Cue Biopharma, Coeptis Therapeutics, NRX Pharmaceuticals, OS Therapies, Century Therapeutics, Telomir Pharmaceuticals, and OUTLOOK THERAPEUTICS. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and infl... More
Equillium Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Equillium's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Equillium upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.49 | |||
| Information Ratio | 0.1209 | |||
| Maximum Drawdown | 43.07 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 19.26 |
Equillium Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Equillium's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Equillium's standard deviation. In reality, there are many statistical measures that can use Equillium historical prices to predict the future Equillium's volatility.| Risk Adjusted Performance | 0.1137 | |||
| Jensen Alpha | 0.9522 | |||
| Total Risk Alpha | 0.4275 | |||
| Sortino Ratio | 0.1468 | |||
| Treynor Ratio | 1.0 |
Equillium February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1137 | |||
| Market Risk Adjusted Performance | 1.01 | |||
| Mean Deviation | 5.33 | |||
| Semi Deviation | 5.24 | |||
| Downside Deviation | 6.49 | |||
| Coefficient Of Variation | 770.33 | |||
| Standard Deviation | 7.88 | |||
| Variance | 62.07 | |||
| Information Ratio | 0.1209 | |||
| Jensen Alpha | 0.9522 | |||
| Total Risk Alpha | 0.4275 | |||
| Sortino Ratio | 0.1468 | |||
| Treynor Ratio | 1.0 | |||
| Maximum Drawdown | 43.07 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 19.26 | |||
| Downside Variance | 42.15 | |||
| Semi Variance | 27.49 | |||
| Expected Short fall | (7.07) | |||
| Skewness | 1.04 | |||
| Kurtosis | 2.4 |
Equillium Backtested Returns
Equillium appears to be extremely dangerous, given 3 months investment horizon. Equillium secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. By reviewing Equillium's technical indicators, you can evaluate if the expected return of 0.99% is justified by implied risk. Please utilize Equillium's Downside Deviation of 6.49, coefficient of variation of 770.33, and Mean Deviation of 5.33 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Equillium holds a performance score of 10. The firm shows a Beta (market volatility) of 1.01, which means a somewhat significant risk relative to the market. Equillium returns are very sensitive to returns on the market. As the market goes up or down, Equillium is expected to follow. Please check Equillium's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Equillium's price patterns will revert.
Auto-correlation | 0.77 |
Good predictability
Equillium has good predictability. Overlapping area represents the amount of predictability between Equillium time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Equillium price movement. The serial correlation of 0.77 indicates that around 77.0% of current Equillium price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.77 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Equillium Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Equillium reported net income of (8.07 Million). This is 102.36% lower than that of the Biotechnology sector and 111.52% lower than that of the Health Care industry. The net income for all United States stocks is 101.41% higher than that of the company.
Equillium Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Equillium's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Equillium could also be used in its relative valuation, which is a method of valuing Equillium by comparing valuation metrics of similar companies.Equillium is currently under evaluation in net income category among its peers.
Equillium Current Valuation Drivers
We derive many important indicators used in calculating different scores of Equillium from analyzing Equillium's financial statements. These drivers represent accounts that assess Equillium's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Equillium's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 108.6M | 35.8M | 25.1M | 26.5M | 30.4M | 28.9M | |
| Enterprise Value | 70.0M | (13.2M) | 2.7M | 8.8M | 10.1M | 9.6M |
Equillium Institutional Holders
Institutional Holdings refers to the ownership stake in Equillium that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Equillium's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Equillium's value.| Shares | Prudential Financial Inc | 2025-06-30 | 39.2 K | Northern Trust Corp | 2025-06-30 | 35 K | Commonwealth Equity Services Inc | 2025-06-30 | 25 K | Baader Bank Inc | 2025-06-30 | 23.7 K | Ground Swell Capital, Llc | 2025-06-30 | 16.6 K | Susquehanna International Group, Llp | 2025-06-30 | 15.1 K | Apollon Wealth Management, Llc | 2025-06-30 | 13.9 K | Tritonpoint Wealth Llc | 2025-06-30 | 13.5 K | Virtu Financial Llc | 2025-06-30 | 10.2 K | Decheng Capital Llc | 2025-06-30 | 4.4 M | Takeda Pharmaceutical Co Ltd | 2025-06-30 | 1.8 M |
Equillium Fundamentals
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (5.55) % | ||||
| Current Valuation | 63.53 M | ||||
| Shares Outstanding | 60.89 M | ||||
| Shares Owned By Insiders | 20.90 % | ||||
| Shares Owned By Institutions | 50.69 % | ||||
| Number Of Shares Shorted | 1.34 M | ||||
| Price To Earning | (6.70) X | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 21.77 X | ||||
| Revenue | 41.09 M | ||||
| Gross Profit | 4.39 M | ||||
| EBITDA | (7.57 M) | ||||
| Net Income | (8.07 M) | ||||
| Cash And Equivalents | 57.56 M | ||||
| Cash Per Share | 1.68 X | ||||
| Total Debt | 384 K | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 3.98 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (19.03 M) | ||||
| Short Ratio | 2.18 X | ||||
| Earnings Per Share | (0.58) X | ||||
| Target Price | 2.5 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.85 | ||||
| Market Capitalization | 95.6 M | ||||
| Total Asset | 25.6 M | ||||
| Retained Earnings | (193.81 M) | ||||
| Working Capital | 18.62 M | ||||
| Current Asset | 60.04 M | ||||
| Current Liabilities | 1.81 M | ||||
| Net Asset | 25.6 M |
About Equillium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Equillium's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Equillium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Equillium based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Equillium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.Moving against Equillium Stock
| 0.74 | DRMA | Dermata Therapeutics | PairCorr |
| 0.68 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.6 | VCYT | Veracyte | PairCorr |
| 0.58 | VCEL | Vericel Corp Ord | PairCorr |
| 0.55 | OSE | OSE Pharma SA | PairCorr |
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.